AI Engines For more Details: Perplexity Kagi Labs You
Alzheimer's Disease: Rivastigmine is approved for the symptomatic treatment of mild to moderate Alzheimer's disease. By inhibiting the breakdown of acetylcholine, it helps improve cognitive function, including memory, attention, and problem-solving abilities, in some patients with Alzheimer's disease.
Parkinson's Disease Dementia: Rivastigmine is also used for the treatment of dementia associated with Parkinson's disease. Parkinson's disease dementia often involves cognitive decline and memory problems, and rivastigmine may help alleviate these symptoms by increasing acetylcholine levels in the brain.
Improvement in Cognitive Function: Rivastigmine has been shown to provide modest improvements in cognitive function, as well as activities of daily living, in some patients with Alzheimer's disease and Parkinson's disease dementia. It may help slow down the progression of cognitive decline and improve overall quality of life.
Side Effects: Common side effects of rivastigmine include gastrointestinal symptoms such as nausea, vomiting, diarrhea, and loss of appetite. These side effects can sometimes be managed by taking the medication with food or adjusting the dosage. Additionally, rivastigmine may cause dizziness, headache, fatigue, and muscle weakness in some individuals.
Dosage Forms: Rivastigmine is available in multiple dosage forms, including oral capsules, oral solution, and transdermal patch. The transdermal patch provides a continuous delivery of the medication and may be associated with fewer gastrointestinal side effects compared to oral formulations.
Titration: Rivastigmine dosage typically starts low and is gradually increased over time to minimize side effects. Healthcare providers may adjust the dosage based on individual patient response and tolerability.
Monitoring: Patients taking rivastigmine may require periodic monitoring of cognitive function, as well as liver function tests and other laboratory parameters, to assess treatment response and detect any potential adverse effects.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| ADHD | 0.2 | 0.2 | |
| Age-Related Macular Degeneration and Glaucoma | 0.2 | -0.2 | |
| Allergic Rhinitis (Hay Fever) | 0.2 | 0.2 | |
| Allergy to milk products | 0.2 | -0.2 | |
| Alopecia (Hair Loss) | 0.4 | 0.4 | |
| Ankylosing spondylitis | 0.9 | 0.9 | |
| Anorexia Nervosa | 0.2 | 0.2 | |
| Antiphospholipid syndrome (APS) | 0.5 | 0.5 | |
| Atrial fibrillation | 0.7 | 0.2 | 2.5 |
| Autism | 0.7 | 0.7 | 0 |
| Barrett esophagus cancer | 0.5 | -0.5 | |
| Bipolar Disorder | 0.2 | 0.2 | |
| Carcinoma | 0.7 | 0.2 | 2.5 |
| Celiac Disease | 0.5 | 0.2 | 1.5 |
| Cerebral Palsy | 0.5 | 0.5 | |
| Chronic Fatigue Syndrome | 0.7 | 0.9 | -0.29 |
| Chronic Kidney Disease | 0.2 | 0.2 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 1.5 | 1.5 | |
| Chronic Urticaria (Hives) | 0.5 | 0.5 | |
| Coagulation / Micro clot triggering bacteria | 0.7 | 0.5 | 0.4 |
| Colorectal Cancer | 0.2 | 0.2 | |
| COVID-19 | 0.8 | 0.6 | 0.33 |
| Crohn's Disease | 0.2 | 0.2 | 0 |
| deep vein thrombosis | 0.5 | -0.5 | |
| Depression | 2.6 | 0.9 | 1.89 |
| Dermatomyositis | 0.5 | 0.5 | |
| Eczema | 0.5 | -0.5 | |
| Endometriosis | 0.7 | 0.7 | |
| Epilepsy | 0.5 | 0.2 | 1.5 |
| Fibromyalgia | 0.3 | 0.3 | |
| Functional constipation / chronic idiopathic constipation | 0.2 | 0.2 | |
| gallstone disease (gsd) | 0.2 | 0.2 | |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.5 | -0.5 | |
| Glioblastoma | 0.5 | -0.5 | |
| Graves' disease | 0.2 | 0.2 | |
| Halitosis | 0.5 | -0.5 | |
| Hidradenitis Suppurativa | 0.5 | 0.5 | |
| hyperglycemia | 0.2 | -0.2 | |
| hypertension (High Blood Pressure | 0.7 | 0.5 | 0.4 |
| Hypoxia | 0.2 | 0.2 | |
| Inflammatory Bowel Disease | 0.6 | 0.4 | 0.5 |
| Insomnia | 0.5 | 0.5 | |
| Intracranial aneurysms | 0.2 | 0.2 | |
| Irritable Bowel Syndrome | 0.2 | -0.2 | |
| Liver Cirrhosis | 0.7 | 0.5 | 0.4 |
| Long COVID | 0.8 | 0.2 | 3 |
| ME/CFS with IBS | 0.5 | 0.5 | |
| ME/CFS without IBS | 0.6 | 0.4 | 0.5 |
| Metabolic Syndrome | 0.7 | 0.7 | 0 |
| Mood Disorders | 2.6 | 0.9 | 1.89 |
| multiple chemical sensitivity [MCS] | 0.5 | 0.5 | |
| Multiple Sclerosis | 1.7 | 1.1 | 0.55 |
| Multiple system atrophy (MSA) | 1 | 1 | |
| Neuropathy (all types) | 0.5 | 0.5 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.5 | 0.5 | |
| Obesity | 0.7 | 0.4 | 0.75 |
| obsessive-compulsive disorder | 0.7 | 0.7 | |
| Osteoarthritis | 0.6 | 0.6 | |
| pancreatic cancer | 0.5 | 0.5 | |
| Parkinson's Disease | 0.7 | 0.5 | 0.4 |
| Polycystic ovary syndrome | 0.2 | 0.2 | |
| Premenstrual dysphoric disorder | 0.2 | -0.2 | |
| Psoriasis | 0.5 | 0.6 | -0.2 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.7 | 0.7 | |
| Schizophrenia | 0.2 | 0.2 | |
| Sjögren syndrome | 0.7 | 0.2 | 2.5 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.5 | 0.5 | |
| Stress / posttraumatic stress disorder | 0.2 | 0.2 | |
| Systemic Lupus Erythematosus | 0.7 | 0.7 | |
| Type 1 Diabetes | 0.5 | -0.5 | |
| Type 2 Diabetes | 0.7 | 0.7 | 0 |
| Ulcerative colitis | 0.6 | 0.2 | 2 |
| Unhealthy Ageing | 0.5 | 0.5 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.